Sartorius Stedim Biotech

DIM

FR0013154002

Medical Equipment, Supplies & Distribution

Market Closed - Euronext Paris Other stock markets 16:35:26 28/06/2024 BST			5-day change	1st Jan Change
153.3 ^EUR	-0.55%		-2.60%	-35.99%

06-27	SARTORIUS STEDIM BIOTECH : Gets a Neutral rating from Barclays	ZD
06-27	The same old winners

SARTORIUS STEDIM BIOTECH : Gets a Neutral rating from Barclays

June 27, 2024 at 11:30 am

Barclays's research confirms his advice and maintains his neutral opinion on the stock. The target price is reduced from EUR 200 to EUR 180.

Latest news about Sartorius Stedim Biotech

SARTORIUS STEDIM BIOTECH : Gets a Neutral rating from Barclays	06-27	ZD
The same old winners	06-27
Sartorius stabilizes after previous day's price slide	06-20	DP
Sartorius on the downswing again - low since 2020 is approaching	06-19	DP
SARTORIUS STEDIM BIOTECH : EPS cut (2023: -13.7%, 2024: -16.4%)	06-03
Sartorius sinks again towards year low	05-16	DP
Transcript : Sartorius Stedim Biotech S.A., Sartorius Aktiengesellschaft - Analyst/Investor Day	05-16
Certain Shares of Sartorius Stedim Biotech S.A. are subject to a Lock-Up Agreement Ending on 8-MAY-2024.	05-07	CI
SARTORIUS STEDIM BIOTECH : Barclays reaffirms its Neutral rating	04-23	ZD
Sartorius Stedim: in the red with brokerage comments	04-22	CF
UBS Cuts Sartorius Stedim Biotech PT, Maintains at Neutral	04-22	MT
SARTORIUS STEDIM BIOTECH : Q1 24: A few positives despite the top-line miss	04-22
SARTORIUS STEDIM : UBS reduces target price	04-22	CF
Global markets live: DocMorris, Microsoft, Oracle, Micron, Netflix...	04-18
Transcript : Sartorius Stedim Biotech S.A., Q1 2024 Earnings Call, Apr 18, 2024	04-18
Transcript : Sartorius Aktiengesellschaft, Sartorius Stedim Biotech S.A., Q1 2024 Earnings Call, Apr 18, 2024	04-18
Sartorius and subsidiary Stedim under pressure after weak figures	04-18	DP
Europe in the green, corporate results hailed	04-18	RE
Sartorius Stedim: Quarterly EPS more than halved	04-18	CF
Sartorius Stedim Biotech S.A. Reports Earnings Results for the First Quarter Ended March 31, 2024	04-18	CI
Sartorius Stedim Biotech Records Lower Q1 Attributable Net Profit, Sales Revenue	04-18	MT
Transcript : Sartorius Stedim Biotech S.A. - Shareholder/Analyst Call	03-26
SARTORIUS STEDIM BIOTECH : Jefferies remains its Buy rating	03-12	ZD
Berenberg: Sartorius Stedim Investors Await 'Several Strong Quarters' for Confidence Boost	02-16	MT
Sartorius gains despite halving dividend	02-09	DP

Chart Sartorius Stedim Biotech

Duration

Period

More charts

Sartorius Stedim Biotech is a leading provider of cutting-edge equipment and services for the development, quality assurance and production processes of the biopharmaceutical industry. Its integrated solutions covering fermentation, filtration, purification, fluid management and lab technologies are supporting the biopharmaceutical industry around the world to develop and produce drugs safely, timely and economically. For next generation processes, Sartorius Stedim Biotech focuses on single-use technologies and value-added services to meet the rapidly changing technology requirements of the industry it serves. Strongly rooted in the scientific community and closely allied with customers and technology partners, the company is dedicated to its philosophy of turning science into solutions on a daily basis. With its own manufacturing and R&D sites in Europe, North America and Asia and a global network of sales companies, Sartorius Stedim Biotech enjoys a worldwide presence. Its key manufacturing and R&D site is in Germany.

Sector

Medical Equipment, Supplies & Distribution

Calendar

19/07/2024 - Q2 2024 Earnings Release

Related indices

STOXX EUROPE 600 (EUR)

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

SARTORIUS STEDIM BIOTECH : EPS cut (2023: -13.7%, 2024: -16.4%)

June 03, 2024 at 08:32 am

More Strategies

Ratings for Sartorius Stedim Biotech

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

153.3 EUR

Average target price

247.2 EUR

Spread / Average Target

+61.23%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
SARTORIUS STEDIM BIOTECH	-35.99%	15.98B
ABBOTT LABORATORIES	-5.60%	181B
MEDTRONIC PLC	-4.45%	101B
BECTON, DICKINSON AND COMPANY	-4.15%	67.54B
DEXCOM, INC.	-8.63%	45.09B
CENCORA, INC.	+9.70%	44.37B
HOYA CORPORATION	+6.13%	40.7B
METTLER-TOLEDO INTERNATIONAL, INC.	+15.22%	29.85B
TERUMO CORPORATION	+14.80%	24.49B
WEST PHARMACEUTICAL SERVICES, INC.	-6.46%	23.99B

Other Medical Equipment, Supplies & Distribution